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Objectives This work analyses the influence of immune status, serum human immu-
nodeficiency virus (HIV) load and hepatitis C virus (HCV) genotypes on the probability
of resolution of HCV infection in HIV-co-infected patients, as well as the evolution of
HCV viremia after antiretroviral therapy.
Patients and methods Forty-five patients with anti-HIV and anti-HCV antibodies were
classified into two groups as a function of the positivity or persistent negativity of HCV
RNA detection (active or recovered HCV infection, respectively). They were treated with
highly active antiretroviral therapy (HAART). Serum HCV RNA was quantified by the
reverse transcription-polymerase chain reaction. HCV genotypes were detected by line
probe assay or by detection of type-specific antibodies.
Results HCV RNA was detectable in 30 (66.6%) out of 45 HIV-infected patients. CD4þ T-
cell counts, HIV viremia, or HCV genotypes were similar in patients with active or
recovered HCV infection. Patients with active HCV infection had a non-significant
decrease of HCV viremia during a follow-up of 12 months (from 6.15 6.32 to
5.96 6.05 log copies/mL). This was not influenced by baseline HCV or HIV viral load,
HCV genotype, or CD4þ T-cell count. The non-significant decrease was present in
patients with or without an immunological response to HAART.
Conclusion HCV genotypes, immune status, or serum HIV load did not influence the
resolution or chronicity of HCV infection in HIV-co-infected individuals. A non-sig-
nificant decrease of HCV viremia in these patients treated with combinations including
antiproteases could be expected.
Keywords Hepatitis C virus, human immunodeficiency virus, chronicity, hepatitis C
virus genotypes
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I N T R O D U C T I O N
Hepatitis C virus (HCV) infection is becoming an
important cause of morbidity and mortality in
patients co-infected with human immunodefi-
ciency virus (HIV) [1,2]. Cross-sectional studies
have detected higher HCV viremia levels in
patients co-infected by HIV [3–6]. Likewise, it
has been demonstrated that HIV infection modi-
fies the natural course of chronic HCV disease,
producing an unusually rapid progression to cir-
rhosis [7].
Controversial results about the influence of the
level of immunodepression on the evolution of
HCV infection have been published [8,9]. One
criticism of these studies is that most did not
include genotype analysis on HCV. Several articles
have suggested an accelerated progression
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towards cirrhosis in non-HIV-infected patients
with chronic HCV infection due to genotypes 1 a
and 1 b [10–13].
Finally, the effects of the treatment with potent
antiretroviral agents on the course of HCV infec-
tion have recently been addressed: stabilization
of HCV viremia has been demonstrated during
combination therapy including antiproteases
[14–16], although the existing data are contro-
versial [17]. The influence of infection by specific
HCV genotypes has not been analysed in this
population.
All the foregoing information concerns the evo-
lution towards advanced stages of liver disease in
patients with chronic HCV infection. Studies of
those parameters implicated in resolution or
chronicity after HCV seroconversion are scarce,
both in HIV-infected and in HIV-non-infected
individuals [18]. The lack of a clinically significant
episode of acute infection in most HCV-infected
patients could explain the absence of this informa-
tion [19].
In the present study we analyse the putative
factors associated with HCV chronicity in a cohort
of HIV-co-infected patients. Also, the influence of
implicated HCV genotypes, baseline HCV viral
load, level of immunodepression and response
to antiretroviral agents on the evolution of HCV
viremia are considered.
P A T I E N T S A N D M E T H O D S
We carried out a prospective study of 45 patients
in the Hospital Universitario Puerta del Mar
(Ca´diz, Spain). This tertiary center serves a
population of 270 000 inhabitants. Cumulative
prevalence of acquired immunodeficiency syn-
drome (AIDS) in our area is 660 per million
inhabitants.
Study population
Patients were consecutively selected from out-
patients who attended the Infectious Disease Unit,
on the basis of simultaneous positivity for anti-
HIV and anti-HCV antibodies. Each one was
asymptomatic with respect to HIV infection and
liver disease, and the echographic study showed
no evidence of portal hypertension.
Patients were classified into two groups on the
basis of the positivity or persistent negativity of
HCV RNA detection (active or recovered HCV
infection, respectively). A factor complicating
the analysis of chronicity of HCV infection is the
possibility of intermittent positivity of serum HCV
RNA determination [20,21]. Thus, a stringent cri-
terion, negative results in each of three samples
taken at 3-month intervals, was required to define
an individual as an HCV non-viremic patient
(recovered HCV infection). Patients with serum
HCV RNA positivity in at least one determination
are referred to as HCV viremic patients (active
HCV infection). The characteristics of the study
population are presented in Table 1.
In accordance with previous articles, the dura-
tion of HCV infection was estimated as the interval
in years from blood transfusion or, in intravenous
drug users, the first sharing of needles [3,22].
Exclusion criteria were: (1) previous anti-HIV
or anti-HCV treatments; (2) immunomodulatory
therapy (corticoids, immunosuppressors, pentox-
yfilline) that could modify the evolution of the
infection; (3) presence of opportunistic diseases
related to HIV infection [23]; (4) active co-infection
by other hepatotropic viruses (active infection by
hepatitis virus B or delta, cytomegalovirus, or
Epstein–Barr virus was absent); (5) evidence of
other toxic (ethanol consumption, drugs), meta-
bolic (serum levels of a1-antitrypsin, ceruloplas-
min and iron were normal), or immunological
(anti-nuclear, anti-smooth muscle and anti-liver
kidney microsomal antibodies were negative)
causes of liver disease; and (6) because of the
possibility of HCV superinfections, active drug
users were excluded.
The study protocol was approved by the Insti-
tutional Ethical Committee and all patients and
controls gave their informed consent.
Laboratory procedures
Sera reactivity for anti-HIV was performed by
enzyme immunoassay (EIA; Abbott Laboratories,
North Chicago, IL, USA) and confirmed by Wes-
tern blot (Pasteur Institute, Paris, France). Serum
HIV load was determined by reverse transcrip-
tion–polymerase chain reaction (RT-PCRl Ampli-
cor HIV, Roche Diagnostics, Basel, Switzerland).
The sensitivity of the assay is 400 RNA copies per
ml of serum.
Sera of all subjects were reactive for anti-HCV,
according to both a second-generation enzyme
immunoassay (EIA-2; Ortho Diagnostic System,
Raritan, NJ, USA) and a second-generation recom-
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binant immunoblot assay (RIBA-2; Ortho Diag-
nostic System). Serum samples were tested for
HCV RNA using the RT-PCR (Amplicor Monitor
HCV Assay, Roche Diagnostics), with primers
derived from the highly conserved 50-untranslated
region, as previously described [24]. The sensitiv-
ity of the assay is 1000 RNA copies per ml of
serum.
In those patients with serum positivity for HCV
RNA, isolates were genotyped by line probe assay
(INNO-LiPA HCV; Innogenetics, Antwerp, Bel-
gium), as previously described [25]. The HCV
genotype nomenclature used in this report is that
proposed by an international panel [26].
In patients whose sera were negative for HCV
RNA and in a random sample of 15 patients whose
sera were positive for HCV RNA, antibodies spe-
cific for genotypes implicated in HCV infection
were detected by the Murex HCV serotyping 1–6
assay, as previously described [27]. This assay
aims to detect the type-specific antibodies against
non-structural region 4-derived epitopes. Serotyp-
ing was performed according to the manufac-
turer’s instructions. The results of this approach
represent serologically defined genotypes. How-
ever, to facilitate their differentiation from geno-
types defined by line probe assay, they will be
designated as serotypes in this article.
Study schedule
Each patient was treated with zidovudine
(200 mg/8 h), zalcitabine (0.75 mg/8 h) and saqui-
navir (600 mg/8 h), as well as with prophylaxis
against opportunistic diseases, according to a pro-
spective protocol [28,29]. They did not receive
treatment against HCV infection. Evaluations
were performed at 3, 6 and 12 months. Clinical
status, haemogram, serum biochemistry, CD4þ T-
cell counts, serum HIV load and, in active HCV
infection, HCV load were analysed in each of these
evaluations. HCV genotyping and serotyping ana-
lyses were performed at the beginning of the
study.
An immunological response to the antiretroviral
regimen was considered when CD4þ T-lympho-
Table 1 Characteristics of the study
population
Parameter
HCV-RNA-positive
patients
(n¼ 30)
HCV-RNA-negative
patients
(n¼ 15)
Age (years) 31.3 6.1 31.1 5.0
Male : female ratio 25 : 5 11 : 4
Risk factors for HIV infection (n,%)
Drug use 29 (96.7) 12 (80.0)
Haemoderivative recipients 1 (3.3) 0 (0)
Heterosexuality 0 (0) 3 (20.0)
Time from the onset of risk
conduct (months)
69.6 42.8 73.1 41.6
Previous opportunistic diseases 4 (13.2) 3 (20.0)
Serum HIV load
(log copies/mL)
4.89 5.19 4.69 5.19
CD4þ T-cell count/mm3 515.0 301.8 483.1 268.9
Genotype/serotype
1 a 16 (53.3) 10 (66.7)
1 b 7 (23.3)
1 a/1 b 7 (23.3)
1? 1 (3.3)
3 10 (33.3) 2 (13.3)
3 a 9 (30.0)
3 b 1 (3.3)
4 4 (13.4) 2 (13.3)
4 c/4 d 4 (13.4)
Multiple types 0 (0) 1 (6.6) y
P¼ 0.032. ySerotypes 1 and 3.
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cyte counts increased by more than 25% above
baseline levels. A virological response was con-
sidered when the HIV load decreased by more
than 1 log copy/mL after 12 months of therapy.
Statistical analysis
Data are presented as mean  standard deviation
or, when indicated, as absolute number and per-
centage. The data from two independent groups
were compared with the Mann–Whitney U-test.
Significance of parameters within each group
was measured by the Wilcoxon matched-pairs
signed rank test. For qualitative variables, w2
with Yates’ correction or Fisher’s exact test was
used.
The relation of co-variates (age, sex, risk factors
for HCV–HIV infection, time from the onset of risk
conduct, CD4þ T-cell counts, serum HIV load and
HCV types) with HCV viremia (dependent vari-
able) was assessed by univariate analysis and the
odds ratios (O.R.), and confidence intervals at 95%
(CI 95%) were determined. A P-value of<0.05 at w2
was considered statistically significant.
R E S U L T S
HCV RNA was detectable in 30 (66.6%) out of 45
HIV-infected patients. Serum transaminase con-
centrations were higher in HCV viremic patients
aspartate aminotransferase (AST): 66.4 49.1 IU/L,
range 15–243 vs. 28.5 22.6 IU/L, range 13–42;
alanine aminotransferase (ALT): 87.2 79.2 IU/L,
range 9–260 vs. 27.3 24.5 IU/L, range 7–41;
P< 0.001 in each case). However, nine (30%)
of the 30 HCV viremic patients presented with
normal serum levels of AST and ALT. No HCV-
RNA-negative patient showed elevation of trans-
aminases above the normal range.
Results of genotyping and serotyping per-
formed in patients with active or past HCV infec-
tion are presented in Table 1. Although a higher
prevalence of HCV type 3 and a lower prevalence
of HCV type 1 was observed in HCV-RNA-
positive patients, this difference did not reach
statistical significance with HCV-RNA-negative
patients. Concordance between serotyping and
genotyping methods was analysed in a sample
of 15 HCV viremic patients (genotype 1 a, 1 b
and 3 a, four cases each; genotype 4 c/4 d, three
cases). In each patient, type-specific antibodies
identified a serotype that was concordant with
the genotype. This includes three samples (20%)
with a single genotype (3 a) but a double serotype
(1þ 3).
With the objective of quantifying the relation-
ship between the several analysed co-variates
and HCV viremia, demographic factors, HIV-
related parameters and HCV types, considered
as independent variables were correlated with
the presence or absence of serum HCV RNA
(dependent variable) by univariate analysis. No
statistically significant association was detected
(Table 2).
In HCV-RNA-positive patients, the mean HCV
viremia was 6.15 6.32 log copies/mL. A signifi-
Table 2 Univariant analysis of putative factors implicated in chronicity of HCV infection in HIV-co-infected patients
Parameter Values
HCV-RNA positive/
HCV-RNA negative Odds ratio
Confidence
interval 95% P
Age >35 years 20/13 0.31 0.03–1.81 0.283
<35 years 10/12
Gender Male 25/11 1.82 0.30–10.25 0.454
Female 5/4
Time from acquisition of disease >5 years 19/8 1.51 0.36–6.39 0.747
<5 years 11/7
HVC type 1 16/10 0.57 0.12–2.43 0.594
3 10/2 3.25 0.54–34.42 0.283
4 4/2 1.00 0.12–12.42 1.000
Multiple types 0/1 0.00 0.00–19.50 0.333
Serum HIV load >6 log copies/mL 7/1 4.26 0.45–205.51 0.236
<6 log copies/mL 23/14
CD4þT cells/mm3 <500 13/9 0.51 0.12–2.13 0.461
>500 17/6
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cantly higher HCV viral load (P< 0.05) was
detected in patients with infection by HCV type
1 a or 1 b than in those infected by types 3 or 4 (type
1 a: 6.43 6.46 log copies/mL; type 1 b: 6.26 6.26
log copies/mL; type 3 a: 5.67 5.90 log copies/mL;
type 4 c/4 d: 5.23 4.88 log copies/mL). Also,
higher viral loads were detected in HCV-RNA-
positive patients with a longer duration of infec-
tion (<5 years (n¼ 11): 5.85 6.20 log copies/mL;
5–10 years (n¼ 14): 6.15 6.26 log copies/mL;
>10 years (n¼ 5): 6.46 6.52 log copies/mL; time
<5 years vs. time >10 years, P¼ 0.020; other com-
parisons, P> 0.05).
A significant correlation between HCV viral
load and the CD4þT-cell count was not detected
(r¼0.24, P> 0.05). HCV viremia was lower in
patients with more than 500 CD4þ T lymphocytes/
mm3 when compared to those with less than
500 CD4þ T lymphocytes/mm3 (5.87 6.04 vs.
6.28 6.41, P> 0.05), although a significant differ-
ence was not reached.
Patients received antiretroviral therapy, includ-
ing an antiprotease, and were followed up for
12 months. At the end of follow-up, a persistent
immune response, defined as an increase in CD4þ
T-cell counts at the 12th month of more than 25%,
was observed in eight (26.7%) patients and a per-
sistent virological response, defined as a decrease
of HIV load of more than 1 log copies/mL, was
observed in 12 (40.0%) patients (Table 3).
Evolution of serum HCV load and transami-
nases is presented in Table 4. In HCV-RNA-posi-
tive patients, no significant difference in serum
transaminases or HCV viral load was detected
between the points of evolution considered. Also,
in HCV-RNA-negative patients, similar values of
serum AST and ALT were detected at every one of
these points (Table 4).
With the objective of evaluating the significance
of specific HCV genotypes, basal serum HCV and
HIV loads, level of immunodepression, and
response or absence of response to antiretroviral
therapy, patients were grouped into several
mutually exclusive categories. Evolution of HCV
viral load as a function of these variables is pre-
sented in Figures 1 and 2. For every variable
considered, no significant difference was detected
between the points of evolution considered.
Table 3 Immune and virological response of HIV patients to antiretroviral treatment
At start of
treatment At 12th month
Mean
increase (%)
Inmune response to antiretroviral therapy (CD4þ cells/mm3)
responders (8 patients, 26.7%) 319.5 194.8 521.0 324.7 67.6 45.9
non-responders (22 patients, 73.3%) 586.1 305.4 543.3 313.1 9.5 8.0
Virological response to antiretroviral therapy (log copies/mL)
responders (12 patients, 40%) 4.72 5.03 3.41 3.60 38.4 39.7
non-responders (18 patients, 60%) 5.12 5.22 4.89 5.12 4.7 1.9
P< 0.001; P¼ 0.020.
Table 4 Evolution of serum HCV load and transaminases in HIV-infected patients
Group Parameter Month 0 Month 3 Month 6 Month 12
HVC-RNA-positive HCV load
(log copies/mL)
6.15 6.32 6.08 6.23 5.97 6.12 5.96 6.05
(n¼ 30) AST (U/L) 66.4 49.1 68.0 35.8 72.2 48.6 63.5 35.0
ALT (U/L) 87.2 79.2 98.8 76.1 94.3 73.6 91.1 69.7
HVC-RNA-negative
(n¼ 15) AST (U/L) 28.5 22.6 26.4 22.9 27.3 21.2 18.0 13.5
ALT (U/L) 27.3 24.5 27.8 39.8 31.1 38.4 14.0 5.3
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 589–597
Pe´rez-Cano et al Resolution vs. chronicity of HCV infection in HIV-co-infected patients 593
D I S C U S S I O N
The rate of HCV viremia (serum HCV RNA posi-
tive) among those with evidence of past HCV
contact (presence of serum anti-HCV antibodies)
was 66.6% in our series, a percentage similar to
that of other series analysing the rates of chronicity
in HIV-non-infected patients [19]. We evaluated
the role of demographics, HCV genotypes,
immune status, or serum HIV load on the possi-
bility of chronicity or resolution of HCV infection.
None of the factors analysed was associated with
the chronicity of HCV infection.
The importance of HCV genotype has been
addressed in several studies. The absence of a
relationship between genotype and evolution is
concordant with the evolution of most RNA
viruses; for example, different serotypes of dengue
virus, another flavivirus, show similar propensi-
ties to cause viral haemorrhagic fever [30].
Our results do not support a positive association
between either serum HIV load or a more pro-
found immunodepression and chronicity of HCV
infection. This was an expected finding [18]. It is
assumed that HCV and HIV infections occur
simultaneously at the time of blood-derivative
transfusion or, in intravenous drug users, in the
first year after the onset of drug abuse [3,20]. A
profound immunodepression in these first stages
of HIV infection is not expected and rates of
resolution of HCV infection in HIV-infected
patients would be similar to those detected in
non-HIV-infected individuals.
Due to the absence of a positive association
between the analysed factors and evolution to
chronicity, alternative explanations must be
sought. Genetic factors [31] and the infecting
HCV load could be determining factors that
explain the chronicity of the infection.
Both HCV-RNA-positive and -negative patients
were followed up for 12 months. The evolution of
HCV viremia in HIV-infected patients treated with
protease inhibitors has been recently addressed. In
the majority of studies, it has been found that HCV
viremia remains without significant changes for
periods ranging from 8 weeks to 9 months in
patients receiving two nucleoside analogues and
either Indinavir, Ritonavir, or Saquinavir [14–17],
although an elevation of CD4þ T-cell counts and a
decrease of HIV viral load occurred [32]. In agree-
ment with these studies, our work has demon-
strated a non-significant decrease of HCV viral
load. Moreover, we have demonstrated that infect-
ing HCV genotype, time of evolution of the HCV
infection, baseline HCV viral load or level of
immunodepression have no influence on the evo-
lution of HCV viremia; these parameters have
been considered as prognostic factors of chronic
HCV infection in non-HIV-infected patients [33].
The absence of modifications of HCV viremia in
HIV-infected patients treated with combinations
including antiproteases contrasts with the ten-
dency towards increases of HCV viremia found
in those patients not receiving anti-HIV treatment
[19,33] or receiving only therapy with two nucleo-
side analogues [34]. There are two possible expla-
nations for this discrepancy. First, immune
reconstitution could be responsible for the control
Figure 1 Evolution of mean HCV viremia at 3, 6 and
12 months. (a) Hepatitis C genotype 1 a (n¼ 7) (^),
genotype 1 b (n¼ 7) (~), genotype 3 a (n¼ 9) (&) and
genotype 4 c/4 d (n¼ 4) (*). (b) Baseline HCV viremia: >6
log copies/mL (n¼ 8) (*), <6 log copies/mL (n¼ 22) (~).
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of HCV viral replication. The absence of differ-
ences between patients with immunological
response and those without response, detected
in the present study, argues against this hypoth-
esis. Second, anti-HIV protease drugs might inter-
act with the recently identified HCV protease [35].
Although this is a possibility, it is evident that this
direct effect on HCV replication is suboptimal:
HCV viremia remained without significant
changes, and did not disappear, in our HIV-
infected patients.
Apart from the importance of chronic liver dis-
ease as a cause of morbidity and mortality, HCV
co-infection has been associated with an acceler-
ated progression of HIV infection and an increased
hepatotoxicity due to antiretroviral drugs [36].
Because control of HCV viremia does not coincide
with the antiretroviral therapy-induced control
of HIV, there is a need for separate treatment
of this chronic HCV infection in selected
patients.
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